Holen Sie sich die Stockscreener-App
1.05
0.00%
0.00
Handel nachbörslich:
1.06
0.01
+0.95%
Maxcyte Inc Aktie (MXCT) Neueste Nachrichten
MaxCyte Inc (MXCT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
MaxCyte Inc (MXCT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
MaxCyte Inc (MXCT) Institutional Confidence - TradingKey
MaxCyte Inc (MXCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
MaxCyte Inc (MXCT) Cash Flow - TradingKey
MXCT|MaxCyte Inc|Price:1.080|Chg%:-0.040 - TradingKey
MaxCyte Inc (MXCT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
MaxCyte, Inc. Revenue Breakdown – DUS:MYE0 - TradingView
MaxCyte Inc (MXCT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
MaxCyte Inc (MXCT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Stifel Maintains MaxCyte(MXCT.US) With Buy Rating, Maintains Target Price $4 - Moomoo
MaxCyte stock surges on Genentech technology license deal By Investing.com - Investing.com South Africa
MaxCyte stock surges on Genentech technology license deal - Investing.com
MaxCyte Enters Technology License Partnership With Genentech - marketscreener.com
Genentech licenses MaxCyte cell engineering technology - Investing.com
MaxCyte licenses cell therapy tech to Genentech for research and manufacturing support - Pluang
Genentech licenses MaxCyte cell engineering technology By Investing.com - Investing.com Canada
MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development - The Manila Times
Genentech Gets Access to MaxCyte Cell-Engineering Platforms - Stock Titan
MaxCyte (MXCT) Proxy filing Summary - Quartr
MaxCyte (MXCT) The 44th Annual William Blair Growth Stock Conference Summary - Quartr
MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026 - The Manila Times
MaxCyte to report Q2 2026 financial results on August 12 - scanx.trade
Enterprise value to revenue forward of MaxCyte, Inc. – DUS:MYE0 - TradingView
MaxCyte(MXCT) Stock Options Chain | Quotes & News - Moomoo
Price to sales forward of MaxCyte, Inc. – DUS:MYE0 - TradingView
Price to earnings forward of MaxCyte, Inc. – DUS:MYE0 - TradingView
ETFs Investing in MaxCyte, Inc. Stocks - TradingView
MaxCyte Inc focuses on cell engineering. Nasdaq-listed MXCT targets long-term growth - Ad-hoc-news.de
MaxCyte (MXCT) Stephens Annual Investment Conference Summary - Quartr
Enterprise value to EBITDA forward of MaxCyte, Inc. – NASDAQ:MXCT - TradingView
MaxCyte stock leans on platform demand. Nasdaq listing stays central. - ad-hoc-news.de
Price to sales forward of MaxCyte, Inc. – LS:A2AGVE - TradingView
Enterprise value to revenue forward of MaxCyte, Inc. – LS:A2AGVE - TradingView
Price to book forward of MaxCyte, Inc. – NASDAQ:MXCT - TradingView
MYE0 Forecast — Price Target — Prediction for 2027 - TradingView
MaxCyte, Inc. Actuals & Estimates (NASDAQ:MXCT) - TradingView
MXCT Forecast — Price Target — Prediction for 2027 - TradingView
Craig-Hallum Maintains MaxCyte(MXCT.US) With Buy Rating - Moomoo
VectorBuilder Partners With MaxCyte® to Advance Clinical-Grade Cell Engineering - Business Wire
Form 4 MaxCyte Inc For: 22 June By Investing.com - Investing.com South Africa
MaxCyte (MXCT) grants RSUs and stock options to director - Stock Titan
MaxCyte (MXCT) director awarded RSUs and stock options in annual grant - Stock Titan
MaxCyte (MXCT) director receives RSUs and options in annual equity grant - Stock Titan
MAXCYTE (NASDAQ: MXCT) director receives RSU and option grants as annual equity award - Stock Titan
MAXCYTE (MXCT) director Cynthia Collins receives RSUs and 49,579-share option grant - Stock Titan
MaxCyte (MXCT) director receives RSUs and 49,579 stock options in new grant - Stock Titan
MaxCyte (MXCT) director Patrick Balthrop receives RSU and stock option grants - Stock Titan
MaxCyte (MXCT) director receives RSU and stock option grant - Stock Titan
MXCT Q1 2026 Earnings: Strong EPS Beat Drives Share Price HigherOne-Time Loss Impact - dars.gov.et
Craig-Hallum Reaffirms Their Buy Rating on MaxCyte (MXCT) - The Globe and Mail
MaxCyte Stockchart levels and volatility on a quiet news day - Ad-hoc-news.de
1.04%
11.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):